Edit
Cadent Therapeutics
http://www.cadenttx.com/Last activity: 01.05.2020
Active - Reference to Novartis
Cadent Therapeutics is creating breakthrough therapies for neurological and psychiatric conditions. The company is rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. Cadent’s first-of-its-kind approach has the potential to bring harmony back to neuronal rhythms, effectively “re-wiring” the brain to treat movement and cognitive disorders. In December 2020 Novartis acquired Cadent for up to $770 million.
Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883
Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883
Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
Employees: 11-50
Total raised: $55M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.05.2020 | Series B | $15M | - |
| 17.11.2018 | Series B | $40M | - |
Mentions in press and media 7
| Date | Title | Description |
| 01.05.2020 | Biopharmaceutical Company Cadent Therapeutics Raises $15 Million | Clinical-stage biopharmaceutical company Cadent Therapeutics announced it raised $15 million Clinical-stage biopharmaceutical company Cadent Therapeutics, a company that is focused on the development of therapies to improve the lives of pat... |
| 29.04.2020 | Cadent Therapeutics Closes $15M Final Equity Tranche of Series B Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced today ... |
| 29.04.2020 | Cadent Therapeutics Closes $15M Final Equity Tranche of Series B Financing | Cadent Therapeutics, a Cambridge, Mass.-based clinical stage biopharmaceutical company, closed $15m final equity tranche of its previously announced $40m Series B financing. The round was led by Cowen Healthcare Investments and Atlas Ventur... |
| 17.11.2018 | Cadent Therapeutics Inks $40M Series B | CAMBRIDGE, MA, Cadent Therapeutics announced that it has raised $40 million in a Series B financing. >> Click here for more funding data on Cadent Therapeutics >> To export Cadent Therapeutics funding data to PDF and Excel, ... |
| 16.11.2018 | Term Sheet — Friday, November 16 | POWERING A COMEBACK Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop BIG BUY: Another day, another large cybersecurity acquisition. Today, BlackBerry announced it will buy Cylance, an AI-based... |
| 15.11.2018 | Cadent Therapeutics Secures $40 Million Series B Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cadent Therapeutics, a company focused on the development of breakthrough therapies to improve the lives of patients with movement and cognitive disorders, today announced that it has raised $40 million in... |
| 15.11.2018 | Cadent Therapeutics Secures $40M Series B Financing | Cadent Therapeutics, a Cambridge, Mass.-based company focused on the development of breakthrough therapies to improve the lives of patients with movement and cognitive disorders, raised $40m in Series B financing. This round was led by Cowe... |